Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer

British Journal of Cancer

Volumn 116, Issue 7, 2017, Pages 964-971

  Kim, Shana J ^a,b   Rosen, Barry ^c,d   Fan, Isabel ^e   Ivanova, Anna ^a,b   McLaughlin, John R ^e,f   Risch, Harvey ^g   Narod, Steven A ^a,b   Kotsopoulos, Joanne ^a,b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f PUBLIC HEALTH ONTARIO   (Canada)

^g YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

ARTICLE; CANCER REGISTRY; ELECTRONIC MEDICAL RECORD; ENDOMETRIOSIS; EVALUATION AND FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HISTOLOGY; HORMONE SUBSTITUTION; INFERTILITY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INTRAUTERINE CONTRACEPTIVE DEVICE; LIFESTYLE MODIFICATION; LONG TERM CARE; MENARCHE; MENSTRUAL CYCLE; MORTALITY; OUTCOME ASSESSMENT; OVARY CARCINOMA; POPULATION AND POPULATION RELATED PHENOMENA; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL; TELEPHONE INTERVIEW; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CANADA; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; MIDDLE AGED; OVARIAN NEOPLASMS; PARITY; PREGNANCY; PROGNOSIS; REPRODUCTIVE HISTORY; TUMOR INVASION; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CANADA; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; EPIDEMIOLOGIC FACTORS; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PARITY; PREGNANCY; PROGNOSIS; REPRODUCTIVE HISTORY; YOUNG ADULT;

EID: 85013135324     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.35     Document Type: Article

References (42)

1. Allison P (1995) Survival Analysis using SAS: A Practical Guide. SAS Institute Inc.: Cary, NC, USA.
2. Barakat RR, Berchuck A, Markman M, Randall ME (2009) Principles and Practice of Gynecologic Oncology. Lippincott Williams and Wilkins: Baltimore, MD, USA.
3. Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87 303 controls. Lancet 371: 303-314.
4. Besevic J, Gunter MJ, Fortner RT, Tsilidis KK, Weiderpass E, Onland-Moret NC, Dossus L, Tjonneland A, Hansen L, Overvad K, Mesrine S, Baglietto L, Clavel-Chapelon F, Kaaks R, Aleksandrova K, Boeing H, Trichopoulou A, Lagiou P, Bamia C, Masala G, Agnoli C, Tumino R, Ricceri F, Panico S, Bueno-de-Mesquita HB, Peeters PH, Jareid M, Quiros JR, Duell EJ, Sanchez MJ, Larranaga N, Chirlaque MD, Barricarte A, Dias JA, Sonestedt E, Idahl A, Lundin E, Wareham NJ, Khaw KT, Travis RC, Rinaldi S, Romieu I, Riboli E, Merritt MA (2015) Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. Br J Cancer 113: 1622-1631.
5. Chang SJ, Bristow RE (2012) Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. Gynecol Oncol 125: 483-492.
6. Chang SJ, Bristow RE, Chi DS, Cliby WA (2015) Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol 26: 336-342.
7. Collaborative Group on Epidemiological Studies of Ovarian CancerBeral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385: 1835-1842.
8. Cramer DW, Welch WR, Scully RE, Wojciechowski CA (1982) Ovarian cancer and talc: a case-control study. Cancer 50: 372-376.
9. Cramer DW, Xu H (1995) Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol 5: 310-314.
10. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE (2007) A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 96: 151-156.
11. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115: 1234-1244.
12. Fathalla MF (1971) Incessant ovulation-a factor in ovarian neoplasia? Lancet 2: 163.
13. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL (2006) Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247: 4-21.
14. Fortner RT, Ose J, Merritt MA, Schock H, Tjonneland A, Hansen L, Overvad K, Dossus L, Clavel-Chapelon F, Baglietto L, Boeing H, Trichopoulou A, Benetou V, Lagiou P, Agnoli C, Mattiello A, Masala G, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Onland-Moret NC, Peeters PH, Weiderpass E, Torhild Gram I, Duell EJ, Larranaga N, Ardanaz E, Sanchez MJ, Chirlaque MD, Brandstedt J, Idahl A, Lundin E, Khaw KT, Wareham N, Travis RC, Rinaldi S, Romieu I, Gunter MJ, Riboli E, Kaaks R (2015) Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. Int J Cancer 137: 1196-1208.
15. Kotsopoulos J, Moody JR, Fan I, Rosen B, Risch HA, Mclaughlin JR, Sun P, Narod SA (2012) Height, weight, BMI and ovarian cancer survival. Gynecol Oncol 127(1): 83-87.
16. Kotsopoulos J, Rosen B, Fan I, Moody J, Mclaughlin JR, Risch H, May T, Sun P, Narod SA (2016) Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol Oncol 140: 42-47.
17. Kushi LH, Kaye SA, Folsom AR, Soler JT, Prineas RJ (1988) Accuracy and reliability of self-measurement of body girths. Am J Epidemiol 128: 740-748.
18. La Vecchia C (2016) Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev.
19. Luan NN, Wu QJ, Gong TT, Vogtmann E, Wang YL, Lin B (2013) Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. Am J Clin Nutr 98: 1020-1031.
20. Mclaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA (2013) Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 105: 141-148.
21. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A (2002) Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 13: 807-811.
22. Nagle CM, Bain CJ, Green AC, Webb PM (2008) The influence of reproductive and hormonal factors on ovarian cancer survival. Int J Gynecol Cancer 18: 407-413.
23. Narod S (2015) Can advanced stage ovarian cancer be cured? Nat. Rev Clin Oncol 13: 255-261.
24. Narod SA, Moody JR, Rosen B, Fan I, Risch A, Sun P, Mclaughlin JR (2013) Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clin Genet 83: 232-237.
25. Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91: 1459-1467.
26. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ (2000) Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11: 111-117.
27. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13: 385-394.
28. Poole EM, Konstantinopoulos PA, Terry KL (2016) Prognostic implications of reproductive and lifestyle factors in ovarian cancer. Gynecol Oncol 142: 574-587.
29. Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, Rosner BA, Webb PM, Cramer DW, Wentzensen N, Terry KL, Tworoger SS (2013) Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Biomarkers Prev 22: 429-437.
30. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC (1990) Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1: 466-473.
31. Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.[comment]. J Natl Cancer Inst 90: 1774-1786.
32. Robbins CL, Whiteman MK, Hillis SD, Curtis KM, Mcdonald JA, Wingo PA, Kulkarni A, Marchbanks PA (2009) Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis. Cancer Epidemiol Biomarkers Prev 18: 2035-2041.
33. Shafrir AL, Babic A, Tamimi RM, Rosner BA, Tworoger SS, Terry KL (2016) Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases. Br J Cancer 115: 1391-1399.
34. Shan W, Liu J (2009) Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 8: 3107-3111.
35. Sopik V, Iqbal J, Rosen B, Narod SA (2015) Why have ovarian cancer mortality rates declined? Part II. Case-fatality. Gynecol Oncol 138: 750-756.
36. Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH, Cushing-Haugen K, Sieh W, Moysich K, Doherty JA, Nagle CM, Berchuck A, Pearce CL, Pike M, Ness RB, Webb PM, Rossing MA, Schildkraut J, Risch H, Goodman MT (2013) Genital powder use and risk of ovarian cancer: a pooled analysis of 8, 525 cases and 9, 859 controls. Cancer Prev Res (Phila) 6: 811-821.
37. Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ. Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjaer SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N. Ovarian Cancer Association Consortium (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium J Natl Cancer Inst 106: djt431.
38. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey Jr JV, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjoholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS (2016) Ovarian Cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol 34: 2888-2898.
39. Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1212-1220.
40. Zhang S, Royer R, Li S, Mclaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA (2011) Frequencies of BRCA1 and BRCA2 mutations among 1, 342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121: 353-357.
41. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, Wang B (2008) Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108: 641-651.
42. Zhou Y, Chlebowski R, Lamonte MJ, Bea JW, Qi L, Wallace R, Lavasani S, Walsh BW, Anderson G, Vitolins M, Sarto G, Irwin ML (2014) Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative. Gynecol Oncol 133: 4-10.